**Supplementary Table 1.**

**Effects of potential confounders on protein levels of fractalkine pathway members.**

*1a. Full Cohort*

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Fractalkine** | **CX3CR1** | **ADAM10** |
| Age (years) | r=0.046, p=0.641 | r=0.156, p=0.113 | r=-0.056, p=0.574 |
| PMI (hours) | r=-0.114, p=0.250 | r=0.080, p=0.421 | **r=-0.260, p=0.008** |
| pH | r=0.146, p=0.139 | r=0.094, p=0.342 | r=-0.146 p=0.140 |
| Storage Duration (months) | r=0.025, p=0.804 | r=0.024, p=0.808 | r=-0.018, p=0.858 |
| Body Mass Index | r=-0.014, p=0.888 | r=0.035, p=0.737 | r=-0.113, p=0.273 |
| Serum C-Reactive Protein | r=-0.059, p=0.566 | r=0.065, p=0.530 | r=0.054 p=0.603 |
| Alcohol None/social; mean ± SD (n=59)  Moderate/heavy; mean ± SD (n=44)  | 0.990 ± 0.3990.974 ± 0.329p=0.927 | 1.009 ± 0.1681.002 ± 0.138p=0.805 | 1.002 ± 0.2830.976 ± 0.228p=0.622 |

*1b. Psychiatric Cohort Only*

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Fractalkine** | **CX3CR1** | **ADAM10** |
| Lifetime Antipsychotic Dose (flu mg equivalent) | r=-0.158, p=0.194 | r=-0.021, p=0.864 | r=0.016, p=0.898 |
| Mood Stabilizers  No; mean ± SD (n=35)  Yes; mean ± SD (n=34)  | 0.977 ± 0.1610.982 ± 0.125p=0.895 | 0.940 ± 0.3301.015 ± 0.356p=0.366 | 1.003 ± 0.2680.950 ± 0.251p=0.403 |
| Antidepressants No; mean ± SD (n=41)  Yes; mean ± SD (n=28) | 0.972 ± 0.1510.990 ± 0.134p=0.611 | 0.945 ± 0.3431.024 ± 0.343p=0.356 | 1.002 ± 0.2720.940 ± 0.240p=0.316 |
| Suicide No; mean ± SD (n=47)  Yes; mean ± SD (n=22) | 0.962 ± 0.1411.016 ± 0.145p=0.153 | 0.974 ± 0.3520.983 ± 0.330p=0.919 | 0.997 ± 0.2720.934 ± 0.230p=0.319 |
| SCZ Subtype  Undifferentiated; mean ± SD (n=) Paranoid; mean ± SD (n=) | 0.962 ± 0.1360.926 ± 0.208p=0.672 | 0.925 ± 0.3781.100 ± 0.210p=0.124 | 0.969 ± 0.2701.063 ± 0.307p=0.482 |

**Supplementary Table 2.**

**Effects of potential confounders on mRNA levels of fractalkine pathway members.**

*2a. Full Cohort*

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Fractalkine** | **CX3CR1** | **ADAM10** |
| Age (years) | r=-0.106, p=0.299 | r=-0.009, p=0.929 | r=0.090, p=0.375 |
| PMI (hours) | r=-0.144, p=0.156 | r=-0.120, p=0.235 | r=0.014, p=0.892 |
| pH | r=-0.028, p=0.784 | r=0.108, p=0.286 | **r=-0.327 p=0.001** |
| RNA Integrity (RIN) | **r=-0.296, p=0.003** | r=0.090, p=0.378 | r**=-0.479 p<0.001** |
| Storage time (months) | r=-0.087, p=0.393 | r=-0.040, p=0.695 | r=-0.030, p=0.765 |
| Body Mass Index | r=0.024, p=0.821 | r=0.095, p=0.363 | r=0.088, p=0.401 |
| Serum C-Reactive Protein | r=0.040, p=0.705 | r=-0.171, p=0.104 | r=0.037, p=0.725 |
| Alcohol None/social; mean ± SD (n=56)  Moderate/heavy; mean ± SD (n=42)  | 18.763 ± 11.46020.257 ± 13.883p=0.500 | 1.097 ± 1.0730.905 ± 0.818p=0.253 | 2.549 ± 1.3492.197 ± 0.993p=0.594 |

*2b. Psychiatric Cohort Only*

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Fractalkine** | **CX3CR1** | **ADAM10** |
| Lifetime Antipsychotic Dose (flu mg equivalent) | r=0.164, p=0.192 | r=0.043, p=0.733 | r=0.212, p=0.090 |
| Mood Stabilizers  No; mean ± SD (n=33)  Yes; mean ± SD (n=32)  | 20.540 ± 15.16318.017 ± 11.732p=0.454 | 1.014 ± 0.9280.853 ± 0.637p=0.663 | 2.435 ± 1.4502.434 ± 1.167p=0.431 |
| Antidepressants No; mean ± SD (n=37)  Yes; mean ± SD (n=28) | 16.938 ± 7.47022.416 ± 18.499p=0.262 | 1.030 ± 0.7550.810 ± 0.846p=0.160 | 2.525 ± 1.4762.314 ± 1.061p=0.357 |
| Suicide No; mean ± SD (n=43)  Yes; mean ± SD (n=22) | 20.468 ± 15.39917.011 ± 8.710p=0.362 | 0.905 ± 0.8460.992 ± 0.705p=0.585 | 2.531 ± 1.3732.246 ± 1.178p=0.373 |
| SCZ Subtype Undifferentiated; mean ± SD (n=25) Paranoid; mean ± SD (n=6) | 22.854 ± 16.06611.980± 9.963p=0.071 | 1.070 ± 0.7821.412 ± 1.359p=0.750 | 2.016 ± 0.6752.465 ± 0.749p=0.468 |

**Supplementary Figure 1: Immunoblots**



Immunoblotting yielded immunoreactive bands at ~55kDa for fractalkine (a), ~50kDa for CX3CR1 (b), and ~70kDa for ADAM10 (c) in human grey matter homogenates.

The expected molecular weight of membrane bound fractalkine is reported to be approximately 95kDa after glycosylation, with the soluble form present at approximately 80kDa. However, fractalkine has been observed at 55kDa in a number of prior studies (Fong et al., 2000; Fonović et al., 2013; Harrison et al., 1998; Hundhausen et al., 2007; Jiang et al., 2017; Lana et al., 2017). It has been suggested that this band likely reflects an alternative cleavage product, potentially via cathepsin S (Fonović et al., 2013; Hundhausen et al., 2007). Alternatively, the band may represent a degradation product of mature glycosylated fractalkine (Lucas et al., 2001) or a fractalkine precursor protein (Garton et al., 2001; Roche et al., 2017).

Validation studies revealed that the fractalkine antibody (#ab25088) recognized a recombinant human fractalkine peptide corresponding to the chemokine domain (residues 25-100). No immunoreactive band was visualized in a negative control experiment omitting the primary antibody. Specificity of this antibody has previously been validated using small interfering RNA (siRNA) knock-down of fractalkine (Morari et al., 2014), and systemic neutralization of fractalkine protein (Liu et al., 2018) in animal models.

Immunostaining for CX3CR1 and ADAM10 yielded specific bands at 50kDa and 70kDa, respectively, in agreement with prior findings (Gutwein et al., 2002; Schäfer et al., 2004) and expected molecular weights of both targets.

References

Fong, A.M., Erickson, H.P., Zachariah, J.P., Poon, S., Schamberg, N.J., Imai, T., Patel, D.D., 2000. Ultrastructure and Function of the Fractalkine Mucin Domain in CX3C Chemokine Domain Presentation. J. Biol. Chem. 275 3781–3786.

Fonović, U.P., Jevnikar, Z., Kos, J., 2013. Cathepsin S generates soluble CX3CL1 (fractalkine) in vascular smooth muscle cells. Biological Chemistry 394 1349–1352.

Harrison, J.K., Jiang, Y., Chen, S., Xia, Y., Maciejewski, D., McNamara, R.K., Streit, W.J., Salafranca, M.N., Adhikari, S., Thompson, D.A., Botti, P., Bacon, K.B., Feng, L., 1998. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. USA 95 10896–10901.

Hundhausen, C., Schulte, A., Schulz, B., Andrzejewski, M.G., Schwarz, N., Hundelshausen, P. von, Winter, U., Paliga, K., Reiss, K., Saftig, P., Weber, C., Ludwig, A., 2007. Regulated Shedding of Transmembrane Chemokines by the Disintegrin and Metalloproteinase 10 Facilitates Detachment of Adherent Leukocytes. The Journal of Immunology 178 8064–8072.

Jiang, T., Zhang, L., Pan, X., Zheng, H., Chen, X., Li, L., Luo, J., Hu, X., 2017. Physical Exercise Improves Cognitive Function Together with Microglia Phenotype Modulation and Remyelination in Chronic Cerebral Hypoperfusion. Front. Cell. Neurosci. 11.

Lana, D., Ugolini, F., Nosi, D., Wenk, G.L., Giovannini, M.G., 2017. Alterations in the Interplay between Neurons, Astrocytes and Microglia in the Rat Dentate Gyrus in Experimental Models of Neurodegeneration. Front. Aging Neurosci. 9.

Lucas, A.D., Chadwick, N., Warren, B.F., Jewell, D.P., Gordon, S., Powrie, F., Greaves, D.R., 2001. The Transmembrane Form of the CX3CL1 Chemokine Fractalkine Is Expressed Predominantly by Epithelial Cells in Vivo. Am. J. Pathol. 158 855–866.

Garton, K.J., Gough, P.J., Blobel, C.P., Murphy, G., Dempsey, P.J., Raines, E.W., 2001. TACE (ADAM17) Mediates the Cleavage and Shedding of Fractalkine (CX3CL1). J. Biol. Chem. 276 37993–38001.

Roche, S.L., Wyse-Jackson, A.C., Ruiz-Lopez, A.M., Byrne, A.M., Cotter, T.G., 2017. Fractalkine-CX3CR1 signaling is critical for progesterone-mediated neuroprotection in the retina. Scientific Reports 7, 43067.

Morari, J., Anhe, G.F., Nascimento, L.F., Moura, R.F. de, Razolli, D., Solon, C., Guadagnini, D., Souza, G., Mattos, A.H., Tobar, N., Ramos, C.D., Pascoal, V.D., Saad, M.J., Lopes-Cendes, I., Moraes, J.C., Velloso, L.A., 2014. Fractalkine (CX3CL1) Is Involved in the Early Activation of Hypothalamic Inflammation in Experimental Obesity. Diabetes 63 3770–3784

Liu, Z., Chen, S., Qiu, C., Sun, Y., Li, W., Jiang, J., Zhang, J.-M., 2018. Fractalkine/CX3CR1 Contributes to Endometriosis-Induced Neuropathic Pain and Mechanical Hypersensitivity in Rats. Front Cell Neurosci 12.

Gutwein, P., Mechtersheimer, S., Riedle, S., Stoeck, A., Gast, D., Joumaa, S., Zentgraf, H., Fogel, M., Altevogt, D.P., 2002. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. The FASEB Journal 17 292–294.

Schäfer, A., Schulz, C., Eigenthaler, M., Fraccarollo, D., Kobsar, A., Gawaz, M., Ertl, G., Walter, U., Bauersachs, J., 2004. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood 103 407–412.